AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer

Urinary Bladder Neoplasms Clinical Trial

Official title:

A Phase II Trial of Neoadjuvant AGEN1884 Plus AGEN2034 in Combination With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04430036
• Other study ID #: CTMS 19-0193
• Secondary ID: HSC20200027H
• Status: Terminated
• Phase: Phase 2
• Start date: October 14, 2020
• Est. completion date: March 14, 2022

Study information

• Verified date: April 2024
• Source: The University of Texas Health Science Center at San Antonio
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase II trial to evaluate the tolerability, efficacy, and immune outcomes of AGEN1884 plus AGEN2034 concurrent with cisplatin and gemcitabine in the neoadjuvant treatment of muscle-invasive, non-metastatic bladder cancer prior to radical cystectomy.

Description:

We will begin with an initial safety run-in to establish the safety of the combination prior to expansion to the full planned phase II. The overall phase II will be an open-label, single arm study in two stages to evaluate the efficacy of the combination in pathologic downstaging of MIBC. Patients will receive four 21-day cycles of neoadjuvant therapy consisting of cisplatin and gemcitabine plus AGEN2034 in all 4 cycles and AGEN1884 in cycles 1 and 3. Patients will proceed to radical cystectomy within 10 weeks after the final dose of this therapy. The primary endpoint of pathologic tumor downstaging will be assessed at the time of cystectomy.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: March 14, 2022
• Est. primary completion date: October 18, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

1. Diagnosis of muscle-invasive, non-metastatic urothelial carcinoma of the bladder, cT2-4, N0-1, M0

2. Eligible to receive cisplatin-based chemotherapy, with eligibility defined as meeting

all of the following criteria:

1. Eastern Cooperative Oncology Group performance status of ¬0-1

2. Creatinine clearance (CrCl) of >50 mL/min, as measured by 24-hour urine collection or estimated by the CKD-EPI equation. Patients with CrCl between 50 - 60 mL/min are eligible for the study but will receive split dose cisplatin

3. Grade < 2 hearing loss

4. Grade < 2 peripheral neuropathy

5. New York Heart Association Class < III heart failure

3. Eligible to receive gemcitabine as dosed here

4. Patients must have organ and marrow function meeting the criteria below:

Absolute neutrophil count > 2,000/mcL Hemoglobin > 9.0 mg/mL Platelets > 100,000/mcL Total bilirubin within normal limits or known to be elevated due to a benign conjugation defect such as Gilbert's syndrome, as evidenced by normal conjugated bilirubin level AST/ALT < 3X institutional normal limits Creatinine clearance (CrCl) > 50 mL/min/1.73m2, as measured with 24 hr urine collection or estimated by CKD-EPI, whichever is greater

5. Signed, written informed consents to allow transfer of tumor tissue and production of peptides and to receive experimental treatment and monitoring if agreeable, or monitoring without experimental treatment otherwise

6. Age =18 years

7. Available fresh tissue from surgical excision. If fresh tissue is not available, archival tissue may be used.

8. Female subjects of childbearing potential must have a negative serum pregnancy test at screening (within 72 hours of first dose of study medication). Non-childbearing

potential (other than by medical reasons) is defined as 1 of the following:

1. = 45 years of age and amenorrheic for >1 year by self-report.

2. Amenorrheic for >2 years without a hysterectomy and oophorectomy, and follicle-stimulating hormone value in the postmenopausal range upon pretrial (screening) evaluation.

3. Status post-hysterectomy, -oophorectomy, or -tubal ligation. If of childbearing potential, female subjects must be willing to use adequate birth control during the study, starting with the screening visit through 120 days after the last dose of study therapy. Male subjects with a female partner(s) of childbearing potential must agree to use a condom throughout the trial, starting with the screening visit through 120 days after the last dose of study therapy. Males with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner. Note: Abstinence is acceptable for both female and male subjects if this is the subject's established and preferred contraception method. Exclusion Criteria

1. Subjects must not have previously received a checkpoint inhibitor ie, anti-PD-1, anti-PD L1, or anti CTLA-4 antibody.

2. Subjects must not have previously received anticancer medications or investigational drugs for the disease under study within the following windows: a. = 28 days for prior monoclonal antibody used for anticancer therapy, with the exception of denosumab b. = 7 days for immunosuppressive treatment for any reason, with the following exceptions: i. Physiologic steroid replacement for adrenal insufficiency (e.g., <10 mg prednisone per day) is permitted. ii. Use of inhaled or topical corticosteroid for radiographic procedures is permitted. c. Systemic corticosteroids < 7 days are not allowed except as defined above. d. = 28 days before first dose of study drug for all other investigational study drugs or devices

3. Has persisting toxicity related to prior therapy of National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE) Grade >1 severity. Note: Sensory neuropathy or alopecia of Grade =2 is acceptable.

4. Has known severe hypersensitivity reactions to fully human monoclonal antibodies (NCI-CTCAE Version 5.0 Grade =3), any history of anaphylaxis, or uncontrolled asthma.

5. Active or history of any autoimmune disease (subjects with diabetes type 1, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible). Patients with a history of inflammatory bowel disease (including Crohn's disease and ulcerative colitis) and autoimmune disorders such as rheumatoid arthritis, systemic progressive sclerosis [scleroderma], Systemic Lupus Erythematosus or autoimmune vasculitis [e.g., Wegener's Granulomatosis] are excluded from this study.

6. Any condition requiring systemic treatment with corticosteroids (>10mg daily prednisone equivalents) or other immunosuppressive medications within 14 days prior to first dose of study drug. Inhaled steroids and adrenal replacement steroids doses >10mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.

7. Uncontrolled intercurrent illness, including but not limited to uncontrolled infection, interstitial lung disease or active, non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or social situations that would limit compliance with study requirements in the opinion of the treating investigator or medical monitor.

8. History of intolerance or allergic reactions attributed to compounds of similar chemical or biologic composition to AGEN1884 or AGEN2034.

9. Women who are pregnant or breastfeeding.

10. Receipt of a live vaccine within 30 days prior to the first dose of study drug.

11. Inability to adhere to the protocol

Related Conditions & MeSH terms

• Urinary Bladder Neoplasms

Intervention

Drug:
• AGEN1884
A fully human monoclonal Anti-PD-1 Antibody
• AGEN2034
A fully human monoclonal Anti-PD-1 Antibody
• Cisplatin
Alkylating antineoplastic agent
• Gemcitabine
Antimetabolite antineoplastic agent

Locations

Country	Name	City	State
United States	Mays Cancer Center	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
The University of Texas Health Science Center at San Antonio

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Correlate Immune Outcomes	To correlate clinical outcomes with immune and biologic endpoints and identify patient and tumor characteristics that can predict treatment responses	2 years
Primary	Pathologic Tumor Downstaging of >T2 to pT0	pT0 or pCR (defined as no residual tumor in bladder and lymph nodes on resected specimen). Surgery should be performed within 6 weeks after completing up to 4 cycles (last dose) of neoadjuvant therapy, but can be done up to 10 weeks after treatment ends to be evaluable. Otherwise this patient must be replaced for response evaluation.	Completion of four 21 day cycles (approximately 10 weeks)
Secondary	Evaluation of Safety and Tolerability of AGEN1884 Plus AGEN2034 Plus Cisplatin and Gemcitabine	Evaluation of safety and tolerability of using Agen1884 plus AGEN2034 plus cisplating and gemcitabine chemotherapy in the neoadjuvant treatment of muscle-invasive bladder cancer prior to radial cystectomy. Number of adverse events assessed between 3-5 using the National Cancer Institution Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0)	Baseline to 90 days
Secondary	Pathologic Downstaging to <T2 Rate	Number of subjects who achieved downstaging of the tumor at completion of the possible 4 chemotherapy cycles.	Baseline to Completion of four 21 day cycles (approximately 10 weeks)
Secondary	Completion of Surgery	Number of subjects that progressed from therapy to surgery	90 days
Secondary	Progression-free Survival at 1 Year	Number of subjects that survived to 1 year from study start without disease progression	1 year